All In Biotech

Drug Trial Radar · NCT07648225

UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

A PhaseⅢ Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Sep 29, 2027

Study completion Nov 3, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients

Conditions

  • Obesity & Overweight

Interventions

  • UBT251 Injection 4.0 mgDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection 6.0 mgDrug

    UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly

  • UBT251 Injection Placebo 4.0 mgDrug

    UBT251 Injection placebo subcutaneously once weekly

  • UBT251 Injection Placebo 6.0 mgDrug

    UBT251 Injection placebo subcutaneously once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body WeightTime frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.